Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;35(6):1141-1158.
doi: 10.1111/fcp.12683. Epub 2021 May 16.

Chronic use of renin-angiotensin-aldosterone system blockers and mortality in COVID-19: A multicenter prospective cohort and literature review

Nathalie Gault  1   2 , Marina Esposito-Farèse  1   3 , Matthieu Revest  4 , Jocelyn Inamo  5 , André Cabié  6 , Élisabeth Polard  7 , Jean-Sébastien Hulot  8   9 , Jade Ghosn  10 , Catherine Chirouze  11 , Laurène Deconinck  10 , Jean-Luc Diehl  12   13 , Julien Poissy  14 , Olivier Epaulard  15 , Benjamin Lefèvre  16   17 , Lionel Piroth  18 , Etienne De Montmollin  19   20 , Eric Oziol  21 , Manuel Etienne  22 , Cédric Laouénan  1   2   20 , Patrick Rossignol  23   24 , Dominique Costagliola  25 , Emmanuelle Vidal-Petiot  26   27 ; French-Covid cohort investigators, study group
Collaborators, Affiliations

Chronic use of renin-angiotensin-aldosterone system blockers and mortality in COVID-19: A multicenter prospective cohort and literature review

Nathalie Gault et al. Fundam Clin Pharmacol. 2021 Dec.

Abstract

Aims: The role of renin-angiotensin-aldosterone system (RAAS) blockers on the course of coronavirus disease 2019 (COVID-19) is debated. We assessed the association between chronic use of RAAS blockers and mortality among inpatients with COVID-19 and explored reasons for discrepancies in the literature.

Methods and results: We included adult hypertensive patients from a prospective nationwide cohort of 3512 inpatients with COVID-19 up to June 30, 2020. Cox proportional hazard models with various adjustment or propensity weighting methods were used to estimate the hazard ratios (HR) of 30-day mortality for chronic users versus non-users of RAAS blockers. We analyzed data of 1160 hypertensive patients: 719 (62%) were male and 777 (67%) were older than 65 years. The main comorbidities were diabetes (n = 416, 36%), chronic cardiac disease (n = 401, 35%), and obesity (n = 340, 29%); 705 (61%) received oxygen therapy. We recorded 135 (11.6%) deaths within 30 days of diagnosis. We found no association between chronic use of RAAS blockers and mortality (unadjusted HR = 1.13, 95% CI [0.8-1.6]; propensity inverse probability treatment weighted HR = 1.09 [0.86-1.39]; propensity standardized mortality ratio weighted HR = 1.08 [0.79-1.47]). Our comprehensive review of previous studies highlighted that significant associations were mostly found in unrestricted populations with inappropriate adjustment, or with biased in-hospital exposure measurement.

Conclusion: Our results do not support previous concerns regarding these drugs, nor a potential protective effect as reported in previous poorly designed studies and meta-analyses. RAAS blockers should not be discontinued during the pandemic, while in-hospital management of these drugs will be clarified by randomized trials. NCT04262921.

Keywords: COVID-19; RAAS blockers; angiotensin antagonists; hypertension; mortality; propensity score.

PubMed Disclaimer

Conflict of interest statement

MR received travel funding from Pfizer, outside the submitted work. APHP, which employs JSH, has received research grants from Bioserenity, Sanofi, Servier, and Novo Nordisk. JSH received speaker, advisory board, or consultancy fees from Amgen, Astra Zeneca, Bayer, Bristol‐Myers Squibb, Novartis, Novo Nordisk, WeHealth, outside the submitted work. BL reports travel funding from ViiV (2019) and Gilead (2020), outside the submitted work. PR reports personal fees (consulting) from Idorsia and G3P and honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, CVRx, Fresenius, Grunenthal, Novartis, Novo Nordisk, Sequana medical, Servier, Stealth Peptides, Ablative Solutions, Corvidia, Relypsa, Vifor, and Vifor Fresenius Medical Care Renal Pharma; outside the submitted work. PR is the cofounder of CardioRenal (outside the submitted work). DC reports HIV grants from Janssen (2017‐2018, 2019‐2020) and MSD France (2015‐2017), personal fees from Janssen (2018), MSD France (2017) and Gilead (2018, 2020) for lectures on HIV, and personal fees from Merck Switzerland (2017) for consultancy on multiple sclerosis, outside the submitted work. EVP received fees and travel funding from Servier, outside the submitted work.

Figures

FIGURE 1
FIGURE 1
Flowchart of patients’ selection from the French COVID Cohort
See this image and copyright information in PMC

References

    1. Richardson S, Hirsch JS, Narasimhan M et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID‐19 in the New York City Area. JAMA. 2020;323:2052–2059. - PMC - PubMed
    1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID‐19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239–1242. - PubMed
    1. Zhou F, Yu T, Du R et al. Clinical course and risk factors for mortality of adult inpatients with COVID‐19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062. - PMC - PubMed
    1. Ferrario CM, Jessup J, Chappell MC et al. Effect of angiotensin‐converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin‐converting enzyme 2. Circulation. 2005;111:2605–2610. - PubMed
    1. Soler MJ, Ye M, Wysocki J, William J, Lloveras J, Batlle D. Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan. Am J Physiol Renal Physiol. 2009;296:F398–F405. - PubMed

Substances

Associated data